Showing results (101-110 of 235) with videos related to
Sort By:
Pageof 24
Cancer|November 21, 2012
Single-fraction radiotherapy versus multifraction radiotherapy for palliation of painful vertebral bone metastases-equivalent efficacy, less toxicity, more convenient: a subset analysis of Radiation Therapy Oncology Group trial 97-14David D Howell, Jennifer L James, William F Hartsell, et al.International Journal of Radiation Oncology, Biology, Physics|October 12, 2013
Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trialJeff M Michalski, Yan Yan, Deborah Watkins-Bruner, et al.International Journal of Radiation Oncology, Biology, Physics|May 6, 2008
Protein kinase A RI-alpha predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86-10Li-Yan Khor, Kyounghwa Bae, Tahseen Al-Saleem, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Living with prostate cancer: patients' and spouses' psychosocial status and quality of lifeLaurel L Northouse, Darlene W Mood, James E Montie, et al.International Journal of Radiation Oncology, Biology, Physics|November 7, 2002
Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy)Janice K Ryu, Kathryn Winter, Jeff M Michalski, et al.International Journal of Radiation Oncology, Biology, Physics|March 6, 2004
Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404Michael D Prados, Wendy Seiferheld, Howard M Sandler, et al.Brachytherapy|April 28, 2015
Combination therapy improves prostate cancer survival for patients with potentially lethal prostate cancer: The impact of Gleason pattern 5Adam L Liss, Eyad I Abu-Isa, Maha S Jawad, et al.JAMA Network Open|November 1, 2023
Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels: A Meta-AnalysisBrandon A Mahal, Lucia Kwak, Wanling Xie, et al.International Journal of Radiation Oncology, Biology, Physics|January 7, 2021
Drivers of Medicare Spending: A 15-Year Review of Radiation Oncology Charges Allowed by the Medicare Physician/Supplier Fee-for-Service Program Compared With Other SpecialtiesMeriem Mokhtech, James H Laird, Sean Maroongroge, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02Li Yan Khor, Jennifer Moughan, Tahseen Al-Saleem, et al.Pageof 24